NO20073928L - Stabilt partikkelformig legemiddel med solifenacin eller salt av dette - Google Patents

Stabilt partikkelformig legemiddel med solifenacin eller salt av dette

Info

Publication number
NO20073928L
NO20073928L NO20073928A NO20073928A NO20073928L NO 20073928 L NO20073928 L NO 20073928L NO 20073928 A NO20073928 A NO 20073928A NO 20073928 A NO20073928 A NO 20073928A NO 20073928 L NO20073928 L NO 20073928L
Authority
NO
Norway
Prior art keywords
solifenacin
salt
particulate
stable particulate
pharmaceutical composition
Prior art date
Application number
NO20073928A
Other languages
English (en)
Inventor
Hiroyuki Umejima
Hiroshi Ohi
Katsumi Saito
Yuko Taketani
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of NO20073928L publication Critical patent/NO20073928L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/06Anti-spasmodics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Stabil partikkelformig farmasøytisk blanding av solifenacin eller salt derav for anvendelse som et farmasøytisk preparat på det kliniske område. Preparatet er i kuleform egnet for påføring av overtrekk, hvor degradering over tid kan bli inhibert, Det partikkelformige farmasøytiske preparat fremstilles ved å anvende et bindemiddel med Tg eller smp lavere enn 174 0C, ved formuleringen av en partikkelformig blanding med solifenacin til et farmasøytisk preparat. Det utføres behandling som påskynder krystallisasjon etter at den partikkelformige farmasøytiske blanding er dannet, og det oppnås en stabilere partikkelformig blanding med solifenacin eller et salt derav.
NO20073928A 2004-12-27 2007-07-26 Stabilt partikkelformig legemiddel med solifenacin eller salt av dette NO20073928L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63838804P 2004-12-27 2004-12-27
JP2005085968 2005-03-24
PCT/JP2005/023771 WO2006070735A1 (ja) 2004-12-27 2005-12-26 ソリフェナシンまたはその塩の安定な粒子状医薬組成物

Publications (1)

Publication Number Publication Date
NO20073928L true NO20073928L (no) 2007-09-18

Family

ID=36614852

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073928A NO20073928L (no) 2004-12-27 2007-07-26 Stabilt partikkelformig legemiddel med solifenacin eller salt av dette

Country Status (8)

Country Link
US (1) US20080103171A1 (no)
EP (1) EP1832288B1 (no)
KR (1) KR101342786B1 (no)
CN (1) CN101141961B (no)
AU (1) AU2005320672B2 (no)
CA (1) CA2591761A1 (no)
NO (1) NO20073928L (no)
WO (1) WO2006070735A1 (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100137358A1 (en) * 1996-11-05 2010-06-03 Dr. Reddy's Laboratories Ltd. Solifenacin compositions
WO2008128028A2 (en) * 2007-04-11 2008-10-23 Dr. Reddy's Laboratories Ltd. Solifenacin compositions
US20050175689A1 (en) * 2003-10-27 2005-08-11 Yamanouchi Pharmaceutical Co., Ltd. Coated fine particles containing drug for intrabuccally fast disintegrating tablet
KR101156406B1 (ko) * 2004-03-25 2012-06-13 아스텔라스세이야쿠 가부시키가이샤 솔리페나신 또는 그의 염의 고형 제제용 조성물
CN101141961B (zh) * 2004-12-27 2011-07-06 安斯泰来制药株式会社 索非那新或其盐的稳定的颗粒状药物组合物
US7815939B2 (en) * 2005-07-20 2010-10-19 Astellas Pharma Inc. Coated fine particles containing drug for intrabuccally fast disintegrating dosage forms
US8568785B2 (en) 2006-07-19 2013-10-29 Asahi Kasei Chemicals Corporation Process for producing spherical base granule comprising easily water-soluble drug
EP2018850A1 (en) * 2007-07-24 2009-01-28 Ratiopharm GmbH Pharmaceutical composition comprising solifenacin or a pharmaceutically acceptable salt thereof
PT2394648T (pt) 2009-02-04 2016-10-03 Astellas Pharma Inc Composição farmacêutica para administração oral
EP2415472A4 (en) * 2009-03-30 2013-02-20 Astellas Pharma Inc SOLID PHARMACEUTICAL COMPOSITION WITH SOLUBENACIN AMORPHIC BODY
EA201291189A1 (ru) 2010-05-07 2013-05-30 Зентива К.С. Фармацевтическая композиция, содержащая солифенацин, и способ его получения
BR112012029461A2 (pt) 2010-05-19 2017-03-01 Astellas Pharma Inc composição farmacêutica contendo solifenacina
SI2590973T1 (sl) 2010-07-05 2017-01-31 Crystal Pharma, S.A.U. Soli solifenacina
WO2012029838A1 (ja) * 2010-08-31 2012-03-08 協和発酵キリン株式会社 口腔内崩壊錠
JP5936542B2 (ja) 2010-09-01 2016-06-22 アステラス製薬株式会社 包装体
EP2638039A1 (de) 2010-11-11 2013-09-18 Hexal AG Kristallines solifenacin-succinat
EP2500013B1 (en) 2011-03-15 2019-10-02 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical composition comprising solifenacin
EP2778167A1 (en) 2013-03-11 2014-09-17 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Stable pharmaceutical composition comprising amorphous solifenacin or its pharmaceutically acceptable salt
KR20150092385A (ko) 2014-02-03 2015-08-13 씨제이헬스케어 주식회사 솔리페나신을 포함하는 안정한 제제 및 이의 제조방법
JP2017078023A (ja) * 2014-02-28 2017-04-27 アステラス製薬株式会社 経口投与用医薬組成物
CN104940152B (zh) * 2014-03-31 2017-12-29 成都国为生物医药有限公司 一种含有琥珀酸索利那新的药物组合物
JP2016079102A (ja) * 2014-10-10 2016-05-16 テバ製薬株式会社 ソリフェナシン含有製剤
JP6805699B2 (ja) * 2016-10-04 2020-12-23 ニプロ株式会社 医薬組成物、医薬組成物の製造方法、及び非晶質体の安定性を向上させる方法
KR102090135B1 (ko) * 2017-07-14 2020-03-17 주식회사 종근당 솔리페나신 또는 이의 약제학적으로 허용가능한 염을 포함하는 구강 붕해정 및 이의 제조방법
KR20210114271A (ko) 2020-03-10 2021-09-23 주식회사 종근당 솔리페나신 또는 이의 약제학적으로 허용가능한 염을 함유하는 약제학적 조성물
WO2021220133A1 (en) * 2020-04-27 2021-11-04 Zim Laboratories Limited Novel multiparticulate pharmaceutical composition of tamsulosin and solifenacin
WO2022117594A1 (en) 2020-12-01 2022-06-09 Adamed Pharma S.A. Orally-administered preparation containing solifenacin and tamsulosin

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8514665D0 (en) * 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
US4870059A (en) * 1985-11-27 1989-09-26 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Dehydration of hydrous matter with anhydrous maltose
US5082669A (en) * 1989-07-20 1992-01-21 Dainippon Pharmaceutical Co., Ltd. Rapid-releasing oral particle pharmaceutical preparation with unpleasant taste masked
US5075114A (en) * 1990-05-23 1991-12-24 Mcneil-Ppc, Inc. Taste masking and sustained release coatings for pharmaceuticals
US5260072A (en) * 1990-08-30 1993-11-09 Mcneil-Ppc, Inc. Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets
YU48263B (sh) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
ES2056548T3 (es) * 1991-09-25 1994-10-01 Barilla Flli G & R Barrita de pan que sabe como el pan y metodo de fabricarla.
TW284688B (no) * 1991-11-20 1996-09-01 Takeda Pharm Industry Co Ltd
JP2682353B2 (ja) 1991-11-20 1997-11-26 武田薬品工業株式会社 経口用医薬組成物およびその製造法
JPH0624001A (ja) 1992-06-05 1994-02-01 Nec Corp インクカートリッジ及びこれを用いたインクジェット記録装置
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
NO2005012I1 (no) * 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
US5912268A (en) * 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
US5607697A (en) * 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
US20040136915A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing atropine
US6221402B1 (en) * 1997-11-20 2001-04-24 Pfizer Inc. Rapidly releasing and taste-masking pharmaceutical dosage form
US6465009B1 (en) * 1998-03-18 2002-10-15 Yamanouchi Pharmaceutical Co., Ltd. Water soluble polymer-based rapidly dissolving tablets and production processes thereof
ES2265439T3 (es) * 2000-08-18 2007-02-16 Pharmacia Corporation Formulacion oral de valdecoxib que se desintegra rapidamente.
US20020119196A1 (en) * 2000-12-21 2002-08-29 Narendra Parikh Texture masked particles containing an active ingredient
KR20030076634A (ko) * 2001-01-30 2003-09-26 데이진 가부시키가이샤 의약 조성물
JP2004530676A (ja) * 2001-04-18 2004-10-07 ノストラム・ファーマスーティカルズ・インコーポレイテッド 持続放出性薬学的組成物のための新規コーティング
CA2447693A1 (en) * 2001-05-31 2002-12-05 Cima Labs Inc. Taste-masking of highly water-soluble drugs
DK1405638T3 (da) * 2001-07-10 2011-04-18 Astellas Pharma Inc Farmaceutisk sammensætning omfattende quinuclidin-3'-yl-1-phenyl-1,2,3,4,-tetrahydroisoquinolin-2-carboxylat til behandling af interstitiel cystitis og/eller abakteriel prostatitis
US20060035923A1 (en) * 2002-06-07 2006-02-16 Rian Van Meeteren Overactive bladder treating drug
MXPA05003398A (es) * 2002-10-29 2005-06-22 Pharmacia & Upjohn Co Llc Compuestos de amonio cuaternario.
JP4523265B2 (ja) * 2002-11-13 2010-08-11 旭化成ファーマ株式会社 排尿障害治療用口腔内崩壊製剤
US20040184995A1 (en) * 2003-03-17 2004-09-23 Yamanouchi Pharmaceutical Co., Ltd. Novel dry powder inhalation for lung-delivery and manufacturing method thereof
DE602004003172T2 (de) * 2003-03-21 2007-09-27 Dynogen Pharmaceuticals Inc., Waltham Verfahren zur behandlung von erkrankungen der unteren harnwege mit antimuskarinika und mit modulatoren der alpha-2-delta untereinheit des kalziumkanals
US20060147531A1 (en) * 2003-07-01 2006-07-06 Mojca Segula Tamsulosin core with a coating of polyvinylpyrrolidone and polyfinylacetate
US20050175689A1 (en) * 2003-10-27 2005-08-11 Yamanouchi Pharmaceutical Co., Ltd. Coated fine particles containing drug for intrabuccally fast disintegrating tablet
RU2006127437A (ru) * 2004-02-06 2008-03-20 Вайет (Us) Соли о-десметилвенлафаксина в виде дисперсных частиц и их применение
WO2005077364A1 (ja) * 2004-02-18 2005-08-25 Yamanouchi Pharmaceutical Co., Ltd. ソリフェナシンの経皮投与製剤およびその経皮透過改善方法
KR101156406B1 (ko) * 2004-03-25 2012-06-13 아스텔라스세이야쿠 가부시키가이샤 솔리페나신 또는 그의 염의 고형 제제용 조성물
CN101141961B (zh) * 2004-12-27 2011-07-06 安斯泰来制药株式会社 索非那新或其盐的稳定的颗粒状药物组合物

Also Published As

Publication number Publication date
EP1832288A4 (en) 2010-02-24
CN101141961A (zh) 2008-03-12
US20080103171A1 (en) 2008-05-01
EP1832288B1 (en) 2012-06-20
KR101342786B1 (ko) 2013-12-19
EP1832288A1 (en) 2007-09-12
KR20070098889A (ko) 2007-10-05
AU2005320672B2 (en) 2011-01-06
WO2006070735A1 (ja) 2006-07-06
CA2591761A1 (en) 2006-07-06
CN101141961B (zh) 2011-07-06
AU2005320672A1 (en) 2006-07-06

Similar Documents

Publication Publication Date Title
NO20073928L (no) Stabilt partikkelformig legemiddel med solifenacin eller salt av dette
NO20063620L (no) Arylanilinderivater som beta2 adrenergiske receptoragonister
WO2009066152A3 (en) Haloallylamine inhibitors of ssao/vap-1 and uses therefor
MX2021000482A (es) Composiciones de fenfluramina y métodos de preparación de las mismas.
NO20081325L (no) Nye doseringsformuleringer
UY30183A1 (es) Derivados de quinolina
DK2041133T3 (da) Derivater af imadazol [1,2-A] pyridine-2-carboxamider, fremstilling deraf og anvendelse deraf i terapeutik
RS52169B (en) STABLE LAKVINIMOD PREPARATIONS
RS20070076A (en) Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases
NO20073959L (no) Kinazolinderivat, fremgangsmate for fremstilling og anvendelse derav for inhibering av vekst av kreftceller
NO20100301L (no) Forbedrete brimonidinsammensetninger for behandling av erytem
SE0401971D0 (sv) Piperidne derivatives
RU2010116863A (ru) Бупропиона гидробромид и его терапевтические применения
DK1856090T3 (da) Substituerede thiophen-derivater som glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser
BRPI0515860A (pt) derivados de tetralin e indano, e uso dos mesmos
DK1778680T3 (da) Spirocykliske cyclohexaderivater
ATE459619T1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
ITBO20110012A1 (it) Composizioni farmaceutiche comprendenti rifaximina e loro uso.
DE602006015509D1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
WO2005072132A3 (en) TRICYCLIC MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-κB ACTIVITY AND USE THEREOF
WO2017062468A8 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
WO2009140341A3 (en) Atorvastatin compositions
DK1869038T3 (da) Substituerede 5,6,7,8-tetrahydro-imidazol[1,2-a]pyridin-2-ylamin-forbindelser og deres anvendelse til fremstilling af lægemidler
MX2010009395A (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y procesos para preparacion de los mismos.
CL2009001267A1 (es) Compuestos derivados de triciclos nitrogenados, con actividad antibacteriana; procedimiento de preparacion; composicion farmceutica que los comprende; para el tratamiento de la tuberculosis.